---
title: "Arvinas (NASDAQ:ARVN) Hits New 12-Month Low  - Here's Why"
description: "Arvinas, Inc. (NASDAQ:ARVN) shares hit a new 12-month low at $9.90, down 43.6% from a previous close of $17.56. Analysts have mixed ratings, with Citigroup lowering its target from $28 to $19, while o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231549244.md"
published_at: "2025-03-12T13:35:03.000Z"
---

# Arvinas (NASDAQ:ARVN) Hits New 12-Month Low  - Here's Why

> Arvinas, Inc. (NASDAQ:ARVN) shares hit a new 12-month low at $9.90, down 43.6% from a previous close of $17.56. Analysts have mixed ratings, with Citigroup lowering its target from $28 to $19, while others set targets as high as $69. The company reported a loss of $0.63 EPS, beating estimates. Insider selling has occurred, with CEO John G. Houston selling over 31,000 shares. Institutional investors hold 95.19% of the stock, which focuses on developing therapies to degrade disease-causing proteins.

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as $10.97 and last traded at $9.90, with a volume of 737957 shares. The stock had previously closed at $17.56.

## Wall Street Analyst Weigh In

-   3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

A number of research analysts have issued reports on the stock. Citigroup reduced their target price on shares of Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday. Stephens began coverage on Arvinas in a report on Monday, November 18th. They issued an "overweight" rating and a $55.00 price objective for the company. BTIG Research assumed coverage on Arvinas in a research note on Tuesday, December 10th. They set a "buy" rating and a $69.00 target price on the stock. Wedbush reissued an "outperform" rating and issued a $57.00 price target on shares of Arvinas in a research note on Tuesday, February 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Arvinas currently has an average rating of "Moderate Buy" and an average target price of $56.58.

**View Our Latest Analysis on Arvinas**

## Arvinas Stock Down 43.6 %

The stock has a market cap of $681.12 million, a P/E ratio of -3.82 and a beta of 1.95. The business has a 50-day simple moving average of $18.22 and a 200-day simple moving average of $22.38.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm posted ($2.53) EPS. On average, analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

## Insider Buying and Selling

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now directly owns 159,121 shares of the company's stock, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,572 shares of company stock valued at $695,030. Insiders own 5.23% of the company's stock.

## Hedge Funds Weigh In On Arvinas

Several large investors have recently added to or reduced their stakes in ARVN. GF Fund Management CO. LTD. bought a new stake in shares of Arvinas during the fourth quarter valued at approximately $28,000. KBC Group NV increased its holdings in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after buying an additional 1,255 shares during the period. Quantbot Technologies LP raised its stake in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after buying an additional 2,601 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Arvinas during the 4th quarter worth about $171,000. Finally, Tema Etfs LLC acquired a new stake in shares of Arvinas during the 4th quarter valued at about $227,000. Institutional investors and hedge funds own 95.19% of the company's stock.

## About Arvinas

(Get Free Report)

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

## Read More

-   Five stocks we like better than Arvinas
-   How to Choose Top Rated Stocks
-   3 Stocks Institutions Are Quietly Dumping
-   Pros And Cons Of Monthly Dividend Stocks
-   Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
-   Consumer Discretionary Stocks Explained
-   Walgreens Boots Alliance: Don’t Write Off This Asset Champ Yet

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Arvinas Right Now?

Before you consider Arvinas, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.

While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [ARVN.US - Arvinas](https://longbridge.com/en/quote/ARVN.US.md)
- [C.US - Citigroup](https://longbridge.com/en/quote/C.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,016 Shares | Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,016 shares at an average price of $11.89, totaling $12,080.24, repre | [Link](https://longbridge.com/en/news/276290048.md) |
| Arvinas Inc expected to post a loss of 59 cents a share - Earnings Preview | Arvinas Inc is expected to report a loss of 59 cents per share and a 41.1% decrease in quarterly revenue to $34.879 mill | [Link](https://longbridge.com/en/news/276448971.md) |
| Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN | Caxton Associates LLP acquired 298,062 shares of Arvinas, Inc., valued at $2.19 million, owning 0.41% of the company. Ot | [Link](https://longbridge.com/en/news/269692818.md) |
| Arvinas (NASDAQ:ARVN) Posts Earnings Results, Beats Expectations By $0.27 EPS | Arvinas (NASDAQ:ARVN) reported quarterly earnings of ($0.48) EPS, exceeding expectations by $0.27. Despite a negative ne | [Link](https://longbridge.com/en/news/264713100.md) |
| Arvinas Reports Promising Phase 3 Trial Results | Arvinas Holding Company (ARVN) announced promising Phase 3 trial results for vepdegestrant, showing significant quality  | [Link](https://longbridge.com/en/news/261859062.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
